WO2023079401A1 - Bouchon pour obturer un tractus de tissu pulmonaire - Google Patents
Bouchon pour obturer un tractus de tissu pulmonaire Download PDFInfo
- Publication number
- WO2023079401A1 WO2023079401A1 PCT/IB2022/060146 IB2022060146W WO2023079401A1 WO 2023079401 A1 WO2023079401 A1 WO 2023079401A1 IB 2022060146 W IB2022060146 W IB 2022060146W WO 2023079401 A1 WO2023079401 A1 WO 2023079401A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plug
- substrate
- polyethylene glycol
- sealing plug
- tissue sealing
- Prior art date
Links
- 238000007789 sealing Methods 0.000 title claims abstract description 33
- 210000004072 lung Anatomy 0.000 title claims abstract description 31
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 95
- 108010010803 Gelatin Proteins 0.000 claims abstract description 76
- 229920000159 gelatin Polymers 0.000 claims abstract description 76
- 235000019322 gelatine Nutrition 0.000 claims abstract description 76
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 76
- 239000008273 gelatin Substances 0.000 claims abstract description 74
- 239000000758 substrate Substances 0.000 claims abstract description 67
- 239000007788 liquid Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 28
- 239000000565 sealant Substances 0.000 claims description 23
- 239000003607 modifier Substances 0.000 claims description 20
- 239000012736 aqueous medium Substances 0.000 claims description 17
- 239000011148 porous material Substances 0.000 claims description 15
- 230000007547 defect Effects 0.000 claims description 13
- 239000006260 foam Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 230000002439 hemostatic effect Effects 0.000 claims description 6
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000000269 nucleophilic effect Effects 0.000 claims description 3
- 239000003805 procoagulant Substances 0.000 claims description 3
- 239000000504 antifibrinolytic agent Substances 0.000 claims description 2
- 239000002872 contrast media Substances 0.000 claims description 2
- 238000005227 gel permeation chromatography Methods 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 claims 1
- 229940082620 antifibrinolytics Drugs 0.000 claims 1
- 239000013003 healing agent Substances 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 230000008961 swelling Effects 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 239000003125 aqueous solvent Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000005520 cutting process Methods 0.000 description 8
- 230000036571 hydration Effects 0.000 description 8
- 238000006703 hydration reaction Methods 0.000 description 8
- 238000009423 ventilation Methods 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 7
- 230000023597 hemostasis Effects 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 201000003144 pneumothorax Diseases 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- -1 general coronary Chemical compound 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- GODZNYBQGNSJJN-UHFFFAOYSA-N 1-aminoethane-1,2-diol Chemical compound NC(O)CO GODZNYBQGNSJJN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010001779 Ancrod Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 1
- 108010027612 Batroxobin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000984642 Cura Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010063195 Surgiflo Proteins 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229960004233 ancrod Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940005486 antimigraine preparations Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960002210 batroxobin Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 108010085662 ecarin Proteins 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 230000009543 pathological alteration Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000003339 pneumostatic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000003429 pore cell Anatomy 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012812 sealant material Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 238000013274 transthoracic needle biopsy Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/104—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
Definitions
- the present invention provides a tissue sealing plug comprising a compressed substrate comprising foamed gelatin having an interconnected pore structure impregnated with liquid polyethylene glycol having a viscosity of about 30 to about 260 cP at room temperature (about 20-25C) and substantially free of non-aqueous solvents, along with methods of using the plug for closing punctures in the lung such as those created by lung biopsies.
- Image-guided percutaneous transthoracic needle biopsy (“PTNB”) is an established procedure for patients with suspected pathologic processes, such as bronchogenic carcinoma. The goal of the procedure is to obtain tissue for cytologic or histologic examination. The procedure is typically performed with image guidance by a radiologist. Imaging modalities utilized include fluoroscopy, computed tomography (CT), and ultrasonography.
- PTNB is classified according to the type of needle. Fine needle aspiration biopsy is performed to provide cytological specimens and larger diameter cutting needles produce histological specimens. Historically, cutting needles have been associated with a relatively high incidence of complications, but with the introduction of automated cutting needles comparable rates between fine needle aspiration and cutting needles have been demonstrated.
- an aspiration (18-22 gauge) or cutting needle (14-20 gauge) is placed under image guidance for sample recovery.
- a coaxial technique may be used to allow for multiple passes within the lung tract and to reduce the number of pleural punctures.
- a thin-walled introducer needle 13-19 gauge is first inserted, localized to the lesion, and subsequently the aspiration or cutting needle is inserted.
- TBNA transbronchial needle aspiration
- EBUS endobronchial ultrasonography
- EBUS-TBNA devices include an ultrasound linear processing array and a retractable needle.
- EBUS-TBNA was originally performed with a dedicated 22-gauge aspiration needle; however, larger 21 -gauge needles were introduced more recently.
- EBUS-TBNA are carried out in the proximal lumen of level 9 bronchi, as they are restricted by the outer diameter of the bronchoscope (6.9 mm).
- BIOSENTRYTM Tract Sealant System AngioDynamics, Inc.
- the BIOSENTRY system resulted in the absence of pneumothorax in 85% of patients which was statistically greater than the control group (69%).
- the solid nature of the BIOSENTRY plug induces only a foreign body giant cell reaction and an encapsulation of the hydrogel by 21 days. Accordingly, a more porous plug would lead to a reduced foreign body reaction and more rapid healing.
- US Patent No. 8,292,918 relates to a composite plug for arteriotomy closure that comprises an elongate substrate member and one or more continuous or discontinuous layers disposed at least in part about the substrate member.
- the plug comprises a distal end, a proximal end, and a lumen connecting the distal and proximal ends, the lumen sized to receive a suture.
- the substrate member may comprise a foamed gelatin and the layers may comprise a hydrogel or hemostatic material.
- the hydrogel if present, may comprise polyethylene glycol in the molecular weight range of about 600 to 6000.
- SURGIFOAM® Absorbable Gelatin Sponges commercially available from Ethicon, Inc., Somerville, NJ, are cross-linked, gelatin-based hemostats in dry, solid, sponge form.
- SURGIFOAM Absorbable Gelatin Sponges are sterile, porcine, absorbable gelatin sponges capable of liquefying within 2 to 5 days when applied to bleeding mucosal regions and are completely absorbed within 4 to 6 weeks.
- SURGIFOAM sponges are available in two shapes, cube or flat. Although gelatin is known to absorb 40 times its weight in blood and swell to up to 200% of its initial volume in vivo, this swelling is relatively slow and results in a low swelling pressure. Accordingly, SURGIFOAM® labeling advices, “[w]hen placed into cavities or closed tissue spaces, minimal preliminary compression is advised, and care should be exercised to avoid overpacking (the sponge expands upon absorption of liquid). SURGIFOAM® Sponge may swell to its original size on absorbing fluids, creating the potential for nerve damage.” SUMMARY OF THE INVENTION
- the present invention provides a tissue sealing plug comprising a compressed substrate comprising foamed gelatin having an interconnected pore structure impregnated with liquid polyethylene glycol having a viscosity of about 30 to about 260 cP at room temperature and substantially free of non-aqueous solvents, wherein the weight ratio of polyethylene glycol to foamed gelatin in the substrate is about 4:1 to about 6.8:1 and the plug has a porosity of less than 30%.
- the present invention also provides a method of closing a lung tract, comprising in sequence: (i) inserting into the lung tract a tissue sealing plug comprising a compressed substrate comprising foamed gelatin having an interconnected pore structure impregnated with liquid polyethylene glycol having a viscosity of about 30 to about 260 cP at room temperature and substantially free of non-aqueous solvents, wherein the weight ratio of polyethylene glycol to foamed gelatin in the substrate is about 4:1 to about 6.8:1 and the plug has a porosity of less than 30%; and (ii) injecting an aqueous solution into the compressed substrate of the tissue sealing plug.
- an improved tissue sealing plug having particular benefits for sealing lung tracts resulting from, for example from PTNB and EBUS-TBNA, may be prepared by impregnating a substrate comprising foamed gelatin with liquid polyethylene glycol having a viscosity of about 30 to about 260 cP at room temperature and substantially free of non-aqueous solvents, wherein the weight ratio of polyethylene glycol to foamed gelatin in the substrate is about 4:1 to about 6.8:1 and the plug has a porosity of less than 30%.
- the plug may be compressed and rolled into a plug due to the impregnation of PEG liquid in the foamed gelatin.
- the plug When impregnated, the plug is conformable and flexible even without the introduction of water. If the plug is maintained in a dry environment, the PEG acts as a binder to hold its shape and provides rigidity.
- the plug When inserted into a lung tract, the plug advantageously, when injected with an aqueous component, hydrates and expands to the shape of the tract, immediately forming a mechanical seal.
- Use of the plug is highly effective to achieve pneumostasis and hemostasis control even in larger tracts resulting from PTNB or EBUS-TBNA procedures.
- Figure 1 is a photograph of the prototype tissue sealing plug of Example 2 prior to use.
- Figure 2 is a photograph of the prototype of Example 2 after insertion.
- Figure 3 is a graph of the PEG molecular weight (Da) versus swelling (%) for the results of Example 2.
- pores As used herein, “foam” or “foamed” means a solid, porous material having pores that are internal or below an exterior facing surface with at least a portion of such pores being open to the surface of the material.
- impregnated with means filled with or containing such that the polyethylene glycol is both absorbed and adsorbed into the substrate. That is, the polyethylene glycol substantially fills the available pores of the foamed gelatin, for example as a result of compression induced capillary action, followed by absorption of the PEG into the bulk phase of the gelatin causing the gelatin fibers to swell. The PEG is additionally be adsorbed into the substrate itself.
- substantially free of non-aqueous solvent means containing less than 1% weight percent, for example less than 0.1% weight percent.
- substantially free of air means containing less than 30% volume percent, for example less than 10% volume percent.
- biocompatible means compatible with living tissue or a living system by not being toxic, injurious, or physiologically reactive therewith and not causing immunological rejection thereby.
- biologically absorbable or “resorbable” means capable of degradation in the body to smaller molecules having a size that allows them to be transported into the blood stream. Such degradation and transportation gradually remove the material referred to from the site of application.
- gelatin can be degraded by proteolytic tissue enzymes to absorbable smaller molecules, whereby the gelatin, when applied to tissue, typically is absorbed within about 4-6 weeks, and when applied to bleeding surfaces or mucous membranes, typically liquefies within 3-5 days.
- hemomostasis means the process by which bleeding diminishes or stops. During hemostasis three steps occur in a rapid sequence.
- Vascular spasm is the first response as the blood vessels constrict to reduce blood loss.
- platelet plug formation platelets stick together to form a temporary seal to cover the break in the vessel wall.
- the third and last step is called coagulation or blood clotting. Coagulation reinforces the platelet plug with fibrin threads that act as a “molecular glue.” Accordingly, a hemostatic material or compound is capable of stimulating hemostasis.
- the foam substrate is composed primarily of a gelatin.
- Gelatin which is a denatured form of the protein collagen, has been used in a variety of wound dressings. Since gelatin gels have a relatively low melting point, they are not very stable at body temperature. Therefore, it is imperative to stabilize these gels by establishing crosslinks between the protein chains. In practice, this is usually obtained by treating the gelatin with glutaraldehyde or formaldehyde. Thus cross-linked gelatin may be fabricated into dry sponges which are useful for inducing hemostasis in bleeding wounds or ground into particulate form.
- gel is used herein to denote a swollen, hydrated polymer network which is essentially continuous throughout its volume.
- a protein gel is composed of an essentially continuous network of linked protein molecules and a liquid (typically aqueous) solvent, which fills the space within the protein matrix.
- the protein matrix exerts a strong viscous drag on the solvent molecules, preventing them from flowing freely.
- the component molecules making up the gel network may be linked by ionic, hydrophobic, metallic or covalent bonds. The covalent bond is the most thermally stable of these bonds.
- a particularly preferred substrate is made from the SURGIFOAM gelatin sponge, which has open cell pore structure, not a closed cell foam. Typical pore cell diameter is 95-450 micrometers.
- the SURGIFOAM gelatin sponge meets the requirements of Absorbable Gelatin Sponge as defined by the United States Pharmacopeia, including the water absorption requirement of absorbing not less than 35 times of its weight of water.
- the tissue sealing plug comprises a substrate of foamed gelatin.
- the substrate may comprise a foamed gelatin.
- the substrate may consist essentially of a foamed gelatin.
- the substrate may consist of a foamed gelatin.
- the gelatin typically originates from a porcine source, but may originate from other animal sources, such as from bovine or fish sources.
- the gelatin may be synthetically made, i.e., by recombinant means.
- the gelatin may be cross-linked. Any suitable cross-linking methods known to a person skilled on the art may be used including both chemical and physical cross-linking methods.
- the gelatin has an interconnected pore structure.
- interconnected pore structure means having an open cell pore structure (rather than a closed pore structure).
- the cell diameter of the pores may be about 95 to about 450 micrometers.
- the substrate may have a variety of shapes.
- the substrate may be cylindrical or spherical.
- a cylindrical substrate may be made, for example, by rolling one or more rectangular pieces into a cylinder.
- a cylindrical substrate may have a longitudinally tapered width, that is, its diameter decreases along its length from one end to the other.
- a suitable gelatin sponge for use in or as the substrate is SURGIFOAM® Absorbable Gelatin Sponge commercially available from Ethicon, Inc.
- Other commercially available absorbable gelatin materials useable in or as the substrate include GELFOAM (Pfizer), CURASPON (Cura Medical), GELITASPON (Gelita Medical), and GELASPON (KDM).
- GELFOAM Pfizer
- CURASPON Cura Medical
- GELITASPON Galita Medical
- KDM GELASPON
- Other gelatin foams meeting the definition of Absorbable Gelatin Sponge set forth in the United States Pharmacopeia including the water absorption requirement of absorbing
- the substrate may optionally include surface features.
- the substrate may comprise lines, ribs, barbs, grooves, notches, slits, channels, spikes, steps and combinations thereof.
- the features may be imparted to the substrate before or after loading with PEG.
- the features may be added by scoring, cutting, or other mechanical means, or imparted to the substrate during molding (described below) via features on the inside surface of the mold.
- the gelatin substrate itself, prior to impregnating with the PEG may contain up to about 10% by weight water.
- the preferred gelatin modifier that impregnates the substrate is composed principally of a polyethylene glycol having a molecular weight (whether as a blend or pure PEG formulation) that is liquid having a viscosity of about 30 to about 260cP at room temperature and is substantially free of non-aqueous solvents.
- a polyethylene glycol having a molecular weight whether as a blend or pure PEG formulation
- PEG acts as a plasticizer for the substrate and provides flexibility to the substrate.
- the stability of the foamed gelatin is not affected, yet the PEG acts as a wetting agent that can further increase the rate of hydration of foamed gelatin.
- the PEG modifier component is substantially free of non-aqueous solvents, such as ethanol, methanol, or acetone. This is advantageous because it enables large diameter plugs (i.e., 20 mm) to be made. Additionally, removal of non-aqueous solvents must be done by evaporation or other means. Removal of large amounts of solvent from a large plug would be time consuming and likely incomplete.
- the PEG modifier component should be substantially anhydrous. That is, the PEG modifier component may contain up to about 10% by weight water. Preferably, the PEG modifier component contains no water.
- the PEG modifier component is liquid at room temperature and at normal atmospheric pressure (1 atm).
- the PEG modifier component will generally consist of one or more PEG-based materials have a molecular weight of about 100 to about 600 Da.
- the PEG modifier component may one or more PEG-based materials having a molecular weight of about 300 to 450 Da.
- the amount of liquid PEG modifier that is introduced into the substrate is such that the weight ratio of liquid PEG to the foamed gelatin is about 4:1 to about 6.8:1. That is, the PEG loading is about 4:1 to about 6.8:1 by weight on the weight of the foamed gelatin in the substrate. As the PEG occupies the pores of the cylinder, as the weight ratio of the PEG is increased, the porosity of the plug decreases. As such, a PEG loading ratio of 4: 1 by weight results in a plug with a porosity of about 30%.
- PEG loading ratio of 5: 1 by weight results in a plug with a porosity of about 20%.
- PEG loading ratio of 6:1 by weight results in a plug with a porosity of about 10%.
- tissue sealing plug may be administered at the same time as, or itself comprise, one or more other biocompatible agents, such as those capable of stimulating hemostasis, wound healing, or tissue healing.
- agents include bioactive and non-bioactive agents including without limitation contrast agents such as iohexol, anti-infectives, such as antibiotics and antiviral agents; analgesics and analgesic combinations; anti-helmintics; antiarthritics; anticonvulsants; antidepressants; antihistamines; anti-inflammatory agents; antimigraine preparations; antineoplastics; anti-parkinsonism drugs; antipsychotics; antipyretics, antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations including calcium channel blockers and beta-blockers such as pindolol and antiarrhythmics; antihypertensives; diuretics; vasodilators, including general coronary, peripheral and cerebral; central nervous system stimulants; hormones, such as estradiol and other steroids, including corticosteroids; immunosuppressives; muscle relaxants; parasympatholytics; psychostimul
- a substrate of desired shape and size is first prepared from a selected foamed gelatin. It is then contacted with the PEG modifier component by dipping, spraying, coating, or other means, such that the PEG modifier component is impregnated into the substrate.
- the PEG-loaded gelatin foam may additionally be compressed manually to substantially remove substantially all the air from the plug.
- the substrate may be compressed prior to, during or after loading of the PEG modifier component.
- Conventional foamed gelatins are rigid and brittle, and difficult to roll or compress and susceptible to tearing and fracture.
- a substrate comprising foamed gelatin that has been impregnated with the liquid PEG modifier component may be loaded into a mold or other vessel having a reduced volume, i.e., about 3 to about 5 times smaller than the starting size (volume) of the substrate.
- the mold may include features on its inside surface to impart structural features to the plug during its preparation.
- the resulting plug comprises PEG modifier component that has been absorbed and adsorbed into the substrate such that the plug has a porosity of less than 30%.
- the plug may have a porosity of less than 10%.
- the “porosity” of the plug is determined by the following method based on the mass of the gelatin substrate and residual PEG measured in the plug.
- the volume of the gelatin substrate and the PEG are first calculated based on their densities.
- the volume of the final plug is determined . The difference between these volumes is used to calculate the porosity of the plug.
- the substrate hydrated with PEG modifier component may be optionally loaded into an applicator.
- Applicators including needles, stylets, and the like are known in the art.
- an 18-gauge needle or coaxial needle may be used as the applicator.
- the PEG-loaded gelatin foam substrate is dried for 8-12 hours under nitrogen or other inert atmosphere at room temperature.
- a tissue sealing plug according to the invention may be made using SURGIFOAM Absorbable Gelatin Sponges and a liquid PEG modifier component having a molecular weight of 300 Da.
- a substrate is first made using two strips of SURGIFOAM Absorbable Gelatin Sponges (each 3 cm x 12.5 cm x 1 cm). The two strips are rolled together to produce a substrate having an initial volume of about initial volume 75 cm 3 . This substrate is compressed using a mold into a cylindrical geometry with a diameter of about 19 mm, a length of about 3 cm, and a volume of about 8.5 cm 3 , about a 4.35-fold decrease in volume relative to its initial size.
- the PEG modifier component is injected into the mold to load about 4:1 to about 6.8:1 by weight of the liquid PEG on the weight of the substrate. This loading ratio saturates the gelatin foam material, causing the gelatin fibers and films to swell, decreasing the surface energy of the gelatin but imparting flexibility to it.
- the PEG loaded substrate is dried of any residual moisture in a nitrogen environment at room temperature overnight. The resulting plug is cohesive and somewhat stiff.
- the plug may have a diameter of about 1 mm to about 28 mm depending on the end use.
- the plug may have a diameter of about 10 mm to about 20 mm.
- the diameter of the plug may be about 1 mm for needle biopsies.
- the diameter of the plug may be about 28 mm for lung tract sealing.
- the plug once rolled in a mold, is forced into a needle, for example an 18-gauge needle.
- the plug is dried of any residual moisture in a nitrogen environment at room temperature overnight.
- the resulting plug has a diameter of 0.41- 1.8 mm.
- the PEG modifier component acts as a neat solvent in this system to introduce flexibility to the otherwise rigid gelatin sponge.
- the gelatin sponge is stable when exposed to PEG modifier component unlike an aqueous solvent.
- tissue sealing plug When such a tissue sealing plug according to the invention is placed into an enclosed geometry, such as a lung tract, the plug expands to fill the geometry. Once implanted, the plug continues to hydrate until osmotic pressure of the plug is balanced by the pressure imposed on the plug by the surrounding tissue.
- the plug may be implanted into a lung tissue tract with the aid of an aqueous medium.
- the aqueous medium is injected into the plug once the plug is placed into the tract.
- the aqueous medium may be injected into the center of the implanted plug using a needle.
- the tip of the needle may be withdrawn along the length of the plug to ensure uniform hydration of the plug with the aqueous medium.
- the injection of the aqueous medium into the substrate of the plug results in hydrodynamic pressure on the plug to force rapid hydration.
- the gelatin substrate’ s ability to swell further increases the rate of hydration.
- PBS Phosphate Buffered Saline
- the plug can potentially return to its initial volume prior to loading of the PEG and expand further due to swelling of the plug, for instance on the order of a 120%, 150%, 180%, or 200% increase in volume.
- a fully hydrated plug according to the invention can swell to about 8.7 times its initial volume prior to loading with PEG (unconstrained).
- the aqueous medium may comprise, for example, water, saline or a buffered aqueous medium.
- the aqueous medium is preferably sterile.
- the aqueous medium may be a saline solution.
- the aqueous medium may be a calcium chloride solution.
- the aqueous medium may be water.
- the aqueous medium may be a buffered aqueous medium.
- Suitable buffering agents are known in the art and may be used, such as Sodium citrate; Citric acid, Sodium citrate; Acetic acid, Sodium acetate; K2HPO4, KH2PO4; Na 2 HPO 4 , NaH 2 PO 4 ; CHES; Borax, Sodium hydroxide; TAPS; Bicine; Tris; Tricine; TAPSO; HEPES; TES; MOPS; PIPES; Cacodylate; SSC; MES, or others.
- the aqueous medium may be Phosphate Buffered Saline (PBS).
- PBS Phosphate Buffered Saline
- the plug may be applied in combination with a biosynthetic, synthetic, or biological liquid sealant to assist with pneumostasis and hemostasis control.
- the liquid sealant can include a liquid solution of a nucleophilic agents: albumin or polyethylene glycol- Amine) and an electrophilic agent (i.e. PEG- Succinimidyl Glutarate) that is pre-mixed immediately prior to use or a biological liquid sealant (i.e., fibrinogen and thrombin).
- electrophilic and/or nucleophilic group containing PEG or PEG (Thiol - CoSeal) components that are suitable for use as hemostats and/or sealants are well-known in the art.
- the liquid sealant can be applied before, during, or after insertion of the plug.
- the liquid sealant should be allowed to cross-link (for example, taking about 30 sec to 5 min) to form a seal within the lung tract and at the surface of the lung preventing air leaks.
- the plug may be inserted into the lung tract using an applicator as known in the art.
- the applicator can be inserted into the tract and retracted as the plug is inserted.
- the plug may be placed into the tract via a coaxial needle that is equal to or less than the diameter of a lung tract.
- the plug is inserted using pneumatic pressure until the plug is implanted in the desired location.
- the plug is held with a cylindrical mesh, moved into place, and the plug is deployed by expanding the mesh.
- Example 1 The following non-limiting examples further illustrate the invention.
- a series of tissue sealing plugs were made using SURGIFOAM® Absorbable Gelatin Sponges with (according to the invention) and without (comparative) polyethylene glycol (molecular weight: 300 Da and liquid at room temperature, with 88-96 cPs or mPas at 20C).
- the plugs fabricated with PEGs were immersed in PEG, saturated, and then compressed into a cylindrical mold, squeezing out excess PEG.
- the SURGIFOAM® sponges had to be more aggressively compressed. 10 mL of PBS was slowly injected into the center of each plug using a needle. As the PBS was injected, the tip of the needle was pulled away along the length of the plug to ensure uniform hydration.
- a volumetric swelling assay was performed on each plug as follows. The plug was placed into a 250 mL graduated cylinder with 30 mL ethanol. The final volume change was recorded. The variation in the results was within the resolution of the test method ( ⁇ 2 mL). Due to this consistency, no statistical analyses could be performed. [0064] The average volumetric swelling of the plugs according to the invention containing PEG was 186%. In contrast, the average volumetric swelling of the comparative plugs not containing PEG was only 104%. In summary, the plugs according to the invention swelled an average of 81% more than the comparative plugs, and much more consistently. The inclusion of PEG300 in the plugs increased the extent and improved the consistency of swelling.
- Tissue sealing plugs according to the invention were evaluated for their ability to achieve pneumostasis in an ex vivo porcine lung model.
- the plugs were made as follows. A SURGIFOAM® Absorbable Gelatin Sponge was manually compressed. The hydrophobic (smooth) side of the sponge was scored using a razor blade with 5 mm spacing between scores. 30 mL PEG300 was added to a container with a similar size as the SURGIFOAM® sponge. The hydrophobic side was placed down first and briefly allowed to absorb PEG300. The sponge was flipped and lightly compressed to absorb the majority of the remaining PEG 300. The sponge was manually rolled and placed into an ultra sized PLAYTEX® Gentle Glide tampon applicator as shown in Figure 1. The prototype was placed in a nitrogen box until the ex-vivo assessment.
- lung plucks were harvested fresh on the day of testing and kept moist until testing. Prior to testing, the lungs were placed on a ventilator to recruit collapsed alveoli (in order to open up collapsed airless alveoli). At the time of testing, lungs were connected to a RESPIRONICS respirator (commercially available from Phillips) to precisely control the pressure during ventilation cycles. The pressure was set to an inspiration pressure of 25 cm water and expiration pressure of 5 cm water (D 20 cm water).
- Lung puncture defects were created with a lung tissue coring device having a diameter of 18 mm.
- the resulting puncture defects had a diameter of approximately 20 mm and a depth of approximately 3 cm.
- the air leak in the defect was assessed as severe with a bubble test. When plugs were applied, the pressure was reduced to inspiration pressure of 10cm water and expiration pressure of 10 cm water (no change) to keep the lungs expanded.
- Figure 2 shows the prototype inserted into a defect. Surgifoam® plug and Evicel fibrin sealant. The liquid sealant was dripped into the defect then the rolled Surgifoam® plug was inserted, followed by additional fibrin sealant to cover the matrix and seal the tissue. No leaks were observed at 20 cm water. A small edge leak was observed when the pressure was increased to 35 cm water. The sealant adhered well to the surrounding tissue.
- Tissue sealing plugs according to the invention were tested with and without liquid PEG sealant in a porcine animal model as follows.
- SURGIFLO tip commercially available from Ethicon
- the tissue sealing plugs were each made as follows. A SURGIFOAM® Absorbable Gelatin Sponge was manually compressed. The hydrophobic (smooth) side of the sponge was scored using a razor blade with 5 mm spacing between scores. 30 mL of PEG300, which was liquid, was added to a container with a similar size as the SURGIFOAM® sponge. The hydrophobic side was placed down first and briefly allowed to absorb PEG300. The sponge was flipped and lightly compressed to absorb the majority of the remaining PEG 300. Two sponges were manually rolled and placed into 20 mL syringe with the tip transected. The prototype was placed in a nitrogen box. [0073] A coring device created a defect in an open setting.
- the lung plug that was removed was 2.5 cm in length when placed under negative pressure within a syringe. Minor bleeding was observed.
- a tissue sealing plug as described above was cut to a length of 2.5 cm to undersize the plug and to provide a place for the PEG sealant to pool. (The excess length was pushed out of the syringe and the plug was cut at the opening using a cutting blade.)
- the lung was held at a constant pressure of 10 cm H2O.
- the plug was inserted into the bottom of the defect.
- 10 mL phosphate buffered saline was injected into the center of the plug via a 21 -gauge needle. As the PBS was injected, the tip of the needle was pulled along the length of the plug to ensure uniform hydration. The plug swelled significantly and applied pressure to the walls of the defect.
- a coring device created a defect of 2.5 cm in length. Moderate bleeding was observed.
- a 3 cm length plug made in accordance with Example 3 was inserted into the bottom of the defect with the intent to oversize the plug.
- 10 mL phosphate buffered saline was injected into the center of the plug via a 21 -gauge needle. As the PBS was injected, the tip of the needle was pulled along the length of the plug to ensure uniform hydration. No leak was observed after 3 minutes at full ventilation; therefore, no sealant was applied.
- Example 3 In another test using the porcine animal model set forth in Example 3, a coring device was used to create a 4 cm length tract. Very significant bleeding (the most observed on the day of testing) was observed. A plug made in accordance with Example 3 was inserted into the bottom of the defect and was oversized by approximately 5 mm in length. 10 mL phosphate buffered saline was injected into the center of the plug via a 21-gauge needle. As the PBS was injected, the tip of the needle was pulled along the length of the plug to ensure uniform hydration. No leak was observed after 3 minutes at full ventilation; therefore, no sealant was applied. The Surgeon stated the plug was “absolutely hemostatic and absolutely pneumostatic.”
- the SURGIFOAM® Absorbable Sponges were manually compressed.
- the hydrophobic (smooth) sides of the sponges were striated using a razor blade with 5 mm spacing between striations.
- the sponges were weighed to obtain an initial weight.
- 30 mL PEG was added to a container with a similar size as the SURGIFOAM® sponge.
- the hydrophobic side was placed down first and briefly allowed to absorb PEG.
- the sponge was flipped and lightly compressed to absorb the majority of the remaining PEG.
- Two sponges were manually rolled and placed into a 20 mL syringe with the tip transected.
- the plug was placed in a nitrogen box overnight.
- the plug was weighed again to obtain a final weight.
- the ends of the plug were transected for uniformity and the plugs were cut to 2 cm length.
- the 2 cm plugs were weighed to obtain a dry weight.
- the plugs were placed in 100 mL lx PBS and allowed to absorb for 10 minutes.
- the plugs were removed from PBS, shaken to remove loose water, and the mass was measured to obtain a wet weight. Swelling (%) was calculated gravimetrically.
- PEG300 was a viscous liquid
- PEG600 was a non-flowing paste
- PEG1000 was a solid at room temperature.
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
Abstract
La présente invention concerne un bouchon d'obturation de tissu comprenant un substrat comprenant de la gélatine expansée imprégnée de polyéthylène glycol qui est liquide à température ambiante, le rapport en poids du polyéthylène glycol à la gélatine expansée dans le substrat étant d'environ 4:1 à environ 6,8:1 et le substrat est sensiblement exempt d'air, ainsi que des méthodes d'utilisation du bouchon pour fermer des perforations de tissu dans le poumon.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163275487P | 2021-11-04 | 2021-11-04 | |
US63/275,487 | 2021-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023079401A1 true WO2023079401A1 (fr) | 2023-05-11 |
Family
ID=84329657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/060146 WO2023079401A1 (fr) | 2021-11-04 | 2022-10-21 | Bouchon pour obturer un tractus de tissu pulmonaire |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023079401A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8292918B2 (en) | 2009-02-20 | 2012-10-23 | Boston Scientific Scimed, Inc. | Composite plug for arteriotomy closure and method of use |
US20210213157A1 (en) * | 2020-01-09 | 2021-07-15 | Ethicon, Inc. | Flexible Gelatin Sealant Dressing with Reactive Components |
-
2022
- 2022-10-21 WO PCT/IB2022/060146 patent/WO2023079401A1/fr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8292918B2 (en) | 2009-02-20 | 2012-10-23 | Boston Scientific Scimed, Inc. | Composite plug for arteriotomy closure and method of use |
US20210213157A1 (en) * | 2020-01-09 | 2021-07-15 | Ethicon, Inc. | Flexible Gelatin Sealant Dressing with Reactive Components |
Non-Patent Citations (2)
Title |
---|
YOUSEM SAMUEL A ET AL: "Pulmonary pathologic alterations associated with biopsy inserted hydrogel plugs", HUMAN PATHOLOGY, SAUNDERS, PHILADELPHIA, PA, US, vol. 89, 1 July 2019 (2019-07-01), pages 40 - 43, XP085732589, ISSN: 0046-8177, [retrieved on 20190502], DOI: 10.1016/J.HUMPATH.2019.04.011 * |
YOUSEM, S.A. ET AL.: "Pulmonary pathologic alterations associated with biopsy inserted hydrogel plugs", HUM PATHOL, vol. 89, 2019, pages 40 - 43, XP085732589, DOI: 10.1016/j.humpath.2019.04.011 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230132953A1 (en) | Plug for lung tissue tract sealing | |
EP1404390B1 (fr) | Dispositifs medicaux a matrice d'eponge poreuse et procedes | |
US9700650B2 (en) | Polysaccharide based hydrogels | |
JP4823476B2 (ja) | 止血用傷用包帯およびその作成方法 | |
EP1389125B1 (fr) | Composition gelatineuse reticulee contenant un agent mouillant | |
US5326350A (en) | Soft tissue closure systems | |
WO2019171215A1 (fr) | Compositions de mousse d'agent de scellement pour applications pulmonaires | |
AU2002320182A1 (en) | Porous sponge matrix medical devices and methods | |
US20230085152A1 (en) | Kit for Composition for Tissue Tract Sealing | |
EP2665425A2 (fr) | Appareil de scellement d'une ponction vasculaire | |
US20200107821A1 (en) | Apparatus and methods for sealing a vascular puncture | |
WO2023079401A1 (fr) | Bouchon pour obturer un tractus de tissu pulmonaire | |
JP2007501688A (ja) | 吸収性スポンジを用いた、止血作用を促進するための改善されたシステム、及び方法 | |
JP2007501688A6 (ja) | 吸収性スポンジを用いた、止血作用を促進するための改善されたシステム、及び方法 | |
US20240115758A1 (en) | Flowable hydrogel hydrocolloid composite sealant | |
JP2024534444A (ja) | 組織経路封止用組成物のためのキット | |
RU2743425C1 (ru) | Гемостатическое средство на основе хитозанового аэрогеля | |
WO2022043795A1 (fr) | Bouchon en mousse polymère durci lyophilisé |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22800796 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |